<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03618797</url>
  </required_header>
  <id_info>
    <org_study_id>HL-PIF-301</org_study_id>
    <nct_id>NCT03618797</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin Versus Pitavastatin/Fenofibrate in Complex-dyslipidemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Pitavastatin versus
      Pitavastatin/Fenofibrate in complex-dyslipidemia patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of the Pitavastatin/Fenofibrate in
      complex-dyslipidemia patients by the reduction of non-HDL-Cholesterol levels compared with
      Pitavastatin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean percentage change of Non-HDL Cholesterol</measure>
    <time_frame>from baseline at week 8</time_frame>
    <description>Change rate of Non-HDL-C after 8 weeks compared to baseline (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of Non-HDL Cholesterol</measure>
    <time_frame>from baseline at week 4</time_frame>
    <description>Change rate of Non-HDL-C after 4 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of LDL-C</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of LDL-C after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of HDL-C</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of HDL-C after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of LDL-C/HDL-C</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of LDL-C/HDL-C after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of TC/HDL-C</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of TC/HDL-C after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of non-HDL-C/HDL-C</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of non-HDL-C/HDL-C after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of VLDL-C</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of VLDL-C after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of TG</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of TG after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of TC</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of TC after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of Apo Al</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of Apo Al after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of Apo B</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of Apo B change after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of Apo Al/Apo B</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of Apo Al/Apo B after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of fibrinogen</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of fibrinogen after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean percentage change of hs-CRP</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>Change rate of hs-CRP after 4 and 8 weeks compared to baseline (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement rate(%) of treatment goals after 4 weeks and 8 weeks</measure>
    <time_frame>from baseline at week 4,8</time_frame>
    <description>LDL-C&lt;100mg/dL &amp; non-HDL-C &lt;130mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>Complex-dyslipidemia</condition>
  <arm_group>
    <arm_group_label>HL-PIF cap.160/2mg + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Livalo tab. 2mg + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pitavastatin ca 2mg
once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HL-PIF cap.160/2mg + Placebo</intervention_name>
    <description>Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg</description>
    <arm_group_label>HL-PIF cap.160/2mg + Placebo</arm_group_label>
    <other_name>Fenofibrate 160mg/Pitavastatin Ca 2mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Livalo tab. 2mg + Placebo</intervention_name>
    <description>Pitavastatin ca 2mg</description>
    <arm_group_label>Livalo tab. 2mg + Placebo</arm_group_label>
    <other_name>Pitavastatin Ca 2mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk patient to Coronary Heart Disease

          -  At visit 1(Screening)

               1. If treated with Pitavastatin 2mg monotherapy 4 weeks prior to this study :
                  LDL-C&lt;100mg/dL and 150mg/dL≤TG&lt;500mg/dL, randomize without run-in period

               2. If non treated with Pitavastatin 2mg monotherapy 4 weeks prior to this study :
                  LDL-C≥100mg/dL and 150mg/dL≤TG&lt;500mg/dL, treatment of Pitavastatin 2mg for 4
                  weeks(run-in period)

          -  LDL-C&lt;100mg/dL and 150mg/dL≤TG&lt;500mg/dL after 4 weeks of Pitavastatin 2mg monotherapy

        Exclusion Criteria:

          -  Subject with acute artery disease

          -  Subject with congestive heart failure(NYHA class III~IV) or uncontrolled arrhythmia

          -  Secondary or iatrogenic dyslipidemia caused by hypothyroidism, nephrotic syndrome etc.

          -  AST or ALT &gt; 2XULN, Serum Creatinine &gt; 2.5mg/dL, Creatinine phosphokinase &gt; 2XULN

          -  Subject with gall bladder disease or pancreatitis

          -  Uncontrolled hypertension

          -  Endocrine or metabolic disease affected on serum lipid or liprotein

          -  Subject with medical history of myopathy or rhabdomyolysis caused by Statin treatment,
             hereditary myopathy or family history

          -  Not eligible to participate for the study at the discretion of investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki-Bae Seung</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2018</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

